PerkinElmer Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, everybody. I'm Luke Sergott. I cover life sciences tools and diagnostics at Barclays. It's my pleasure to have Prahlad Singh from PerkinElmer. And with that, if you want to make a couple of comments, and then we can just dig into some questions, if you'd like.
Sure, Luke. Thank you. It's great to see everyone. It's good to meet in person. I think sort of to kick it off, Luke, maybe just talk about the company a little bit.
As you see the process of transformation that we have gone through over the past 5 years, we feel really good about where we are, obviously, covered over the last 24 months has been a major driver and a major factor in the company, but it has also given us the opportunity to continue to transform our portfolio. And where we stand today, 80% of PerkinElmer is in Life Sciences and Diagnostics.
And 3/4 of our revenue comes from consumables, reagents, assays, software
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |